Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation to study esophageal lesions. The esophageal protection probe will not be used.

Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation, using the esophageal protection probe EnsoETM

Atrial Fibrillation

Catheter Ablation

Esophageal Fistula

Esophageal Diseases

Arrhythmias, Cardiac

The EnsoETM is a device with a esophageal probe that can provide temperature adjustment

EnsoETM

Hospital de la Santa Creu i Sant Pau

Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study.

Evaluation of Esophageal Damage During Conventional Pulmonary Vein Ablation Procedures and Potential Strategies to Protect the Esophagus. Pilot Study.

Presence of esophageal lesions will be determined after ablation using esophagogastroscopy.

Degree of esophageal lesions will be determined after ablation using esophagogastroscopy. Degree of esophageal lesions severity will be determined according to the Zargar endoscopy classification (0, I, IIa, IIb, IIIa, IIIb, IV)

Presence of esophageal lesions will be determined after ablation using magnetic resonance imaging

Recurrence of atrial fibrillation after catheter ablation will be determined in the follow-up:
clinically, as episodes with high clinical suspicion of being atrial fibrillation despite no ECG documentation
documented in ECG or in 24-hours holter monitoring, and defined as an episode lasting more than 30 seconds. 24-hours holter monitoring will be performed 3, 6 and 12 months after catheter ablation

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Patients referred for catheter ablation of atrial fibrillation (either cryoablation or radiofrequency ablation (1/1)) will be randomized to either receive or not (1/1) an esophageal temperature adjustment EnsoETM device, to evaluate its role for esophageal protection.

Obesity

Weight Loss

Body Weight

Morbid Obesity

450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches.
30-day post-embolization endoscopic biopsy

Left gastric artery embolization

Bariatric Embolization Trial for the Obese Nonsurgical

Safety outcomes involving the use of left gastric artery embolization

Concentration of Ghrelin-producing cells pre-embolization obtained through endoscopic biopsy and measured by cells per milliliter, will be subtracted from the concentration of Ghrelin-producing cells obtained post-embolization from endoscopic biopsy. This value will be converted into a percentage change and reported.

University of Calgary

Calgary Adult Bariatric Surgery Clinic

Peter Lougheed Center, Mayfair Diagnostics

Obese patients undergoing Local Anesthetics and Transnasal Endoscopy.

Bariatric Surgery Candidate

Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery

transnasal endoscopy

Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.

Local Anesthetics,Topical

Alpha Institute of Gastroenterology - HC/UFMG Rua Alfredo Balena, 110 - 2. Cycling - Santa Efigênia.

Transnasal Endoscopy in Obese Patients Are Candidates for Bariatric Surgery

Transnasal Endoscopy in Obese Patients Are Candidates for Bariatric Surgery: Feasibility, Tolerance, Security and Cost-effectiveness.

The exam will be considered feasible if the appliance reaches the second duodenal portion and is performed retroflexão, allowing the visualization of all portions of the digestive system and the achievement of biopsies if necessary.
All patients will complete a questionnaire 15 to 30 minutes after the transnasal endoscopy and will be released next to the house.
All of this information and the results will be compared with the main data in the literature. Bivariate analyzes shall be calculated from the test "t" test for continuous variables and the chi-square test or Fisher exact test for categorical variables. Proportions will be reported by categorical data; and mean, median and standard deviation for continuous variables. P values less than 0.05 are considered statistically significant.

Participants can be identified by the number of medical records and phone contacts have been duly authorized by the institution responsible.

Amaury Teixeira Xavier

Principal Investigator

Federal University of Minas Gerais

The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
The control group will be made of individuals who do not meet the qualifications for a liver biopsy.

The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD.

The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH.

An additional 5 ml of whole blood and 5 ml of serum will be collected and stored by a research coordinator, nurse, research assistant, or investigator for analysis of specific biomarkers to include Hyaluronic acid, CK-18 (M30), FGF-21, Mac-2BP, FAS, AFP, YKL-40, Alpha-2-macroglobulin and a panel of 46 fatty acids during the liver biopsy appointment.

Non-Alcoholic Fatty Liver Disease

Non Alcoholic Steatohepatitis

non-applicable

San Antonio Military Medical Center

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults

Determine the prevalence of NAFLD in military beneficiaries between ages 18 to 80. This will be determined by the % of subjects determined to have NAFLD via liver biopsy.

Determine the prevalence of NASH in military beneficiaries between ages 18 to 80. This will be determined by the % of subjects determined to have NASH via liver biopsy.

% fat in the liver determined via MRI and LiverMultiScan software

Liver stiffness will be determined via kPa value from Fibroscan

Liver stiffness will be determined via kPa value from MRE

determined by a pathologist reading liver biopsy slides and Brunt scoring system

Determine the prevalence and severity of colon polyps within the population of subjects identified as having NAFLD and correlate these findings to those without NAFLD.

Determine the prevalence and severity of CAD by CCTA and CAC scoring within the population of subjects identified as having NAFLD. Prospectively follow patients undergoing CCTA/CAC scoring for major cardiovascular events (myocardial infarction, stroke/TIA, coronary revascularization, or death).

Determine the prevalence and severity of endothelial dysfunction with peripheral tonometry within the population of subjects identified as having NAFLD. Prospectively follow patients undergoing with peripheral tonometry for major cardiovascular events (myocardial infarction, stroke/TIA, coronary revascularization, or death).

Determine the prevalence of diastolic dysfunction with transthoracic echocardiography within the population of subjects identified as having NAFLD

esophageal and gastric varices/obezita

Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study.

Bariatric Embolization Trial for the Obese Nonsurgical

Transnasal Endoscopy in Obese Patients Are Candidates for Bariatric Surgery

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults

Najkompletnejšia databáza liečivých bylín podporovaná vedou